Antitrust Class Action Review – 2025

1. $2.8 billion – In Re Blue Cross Blue Shield Antitrust Litigation , Case No. 13-CV-20000 (N.D. Ala. Dec. 5, 2024) (preliminary settlement approval granted to resolve claims with Blue Cross Blue Shield operating companies by healthcare providers claiming that the payors conspired to reduce competition by, among other things, allocating geographic markets, resulting in lower reimbursement amounts to providers). 2. $2.78 billion – In Re College Athlete NIL Litigation , Case No. 20-CV-3919 (N.D. Cal. Oct. 7, 2024) (preliminary settlement approval granted to resolve claims with former college athletes who filed an antitrust class action seeking compensation allegedly denied to them for decades before the Supreme Court overturned the NCAA’s compensation ban). 3. $580 million – Iowa Public Employees’ Retirement System, et al. v. Bank Of America Corp. Litigation, Case No. 17 Civ. 6221 (S.D.N.Y. Sept. 4, 2024) (final settlement approval granted in a class action to resolve claims alleging that the defendants conspired to block and boycott new offerings that would have increased competition and improved the efficiency and transparency of the market). 4. $418 million – Burnett, et al. v. the National Association Of Realtors , Case No. 19-CV-332 (W.D. Mo. Nov. 26, 2024) (final settlement approval granted in a group of class actions to resolve claims that broker commission rules caused home sellers across the country to pay inflated fees). 5. $385 million – In Re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation , Case No. 13-MD-2445 (E.D. Pa. Feb. 27, 2024) (final settlement approval granted in a class action to resolve claims brought by states, insurers, and buyers of a new dissolvable strip version of Suboxone to the market, encouraging the move from tablets to strips by misrepresenting to the U.S. Food and Drug Administration that the tablets posed a risk to children of accidental consumption). 6. $375 million – Le, et al. v. Zuffa LLC , Case No. 15-CV-1045 (D. Nev. Mar. Oct. 22, 2024) (preliminary settlement approval granted in a class action to resolve claims that fighters’ wages were suppressed by up to $1.6 billion). 7. $284 million – Henry, et al. v. Brown University, et al., Case No. 22-CV-125 (N.D. Ill. July 19, 2024) (final settlement approval granted to settle six related class actions resolving claims that the universities colluded to limit the amount of need-based financial aid provided to undergraduates). 8. $275 million – In Re Generic Pharmaceuticals Pricing Antitrust Litigation , Case No. 16-MD-2774 (E.D. Penn. Dec. 17, 2024 ) (settlement reached in a class action to resolve claims from consumers, insurers and benefit funds that allegedly overpaid for generic prescription drugs between 2009 and 2019). 9. $265 million – In Re Generic Pharmaceuticals Pricing Antitrust Litigation , Case No. 16-MD-2724 (E.D. Penn. June 21, 2024) (preliminary settlement approval granted for a class action to resolve claims by direct purchasers, end-payors and states alleging that multiple makers of generic drugs conspired to keep the prices on their products high, in violation of state laws and the federal Sherman Act). 10. $250 million – Burnett, et al. v. The National Association Of Realtors , Case No. 19-CV-332 (N.D. Ill. Aug. 8, 2024) (preliminary settlement approval granted with defendant Berkshire Hathaway in a class action to resolve claims that broker commission rules caused home sellers across the country to pay inflated fees).

Made with FlippingBook - professional solution for displaying marketing and sales documents online